Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Favorable Long-Term PIII Results Published for Collategene: AnGes MG
December 20, 2010
- Revolade Benefits Patients with Intractable ITP: Prof. Ikeda
December 20, 2010
- Daiichi Sankyo Subsidiary Luitpold Acquires ROXRO PHARMA
December 20, 2010
- Daiichi Sankyo Completes Enrollment for Edoxaban PIII Trial
December 20, 2010
- Norspan Useful in Getting Doctors Conversant with Opioids: Prof. Ogawa
December 20, 2010
- Sanofi-aventis Extends Tender Offer for Genzyme Shares
December 20, 2010
- Novel Anticoagulants Gaining Popularity: Dr Yamashita
December 20, 2010
- Fixed-Dose Combination Eye Drops Improve Compliance: Dr Araie
December 20, 2010
- Mediscience to Acquire CRO Business from Tokyo Clinical CRO
December 20, 2010
- Industry Support Essential for iPS Cell Drug Discovery: Prof. Yamanaka
December 20, 2010
- NCGM Compiles Manual for Selection of Antidiabetic Drugs for GPs
December 20, 2010
- MTPC Takes Confidence-Building Measures
December 20, 2010
- JPMA Willing to Support iPS Drug Discovery: President Hasegawa
December 20, 2010
- Eisai, SymBio: Anticancer Agent TREAKISYM
December 20, 2010
- Sanofi Pasteur to Enhance Its Presence in Japan: General Manager Perraudin
December 20, 2010
- NPhA Casts Doubt on Drug Wholesalers' Rx Pharmacy Business
December 20, 2010
- Takeda, Daiichi Sankyo, Astellas Lead Drug Firms' Corporate Image Ranking
December 20, 2010
- Kyorin Turns Down Sawai's Merger Proposal Again
December 20, 2010
- NBI Takes Over Mobic Marketing from Daiichi Sankyo
December 13, 2010
- Lubiprostone Shows Favorable Safety, Tolerability in PIII: Sucampo, Abbott
December 13, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…